JERUSALEM, Nov 6 (Reuters) - Teva Pharmaceutical

Industries reported a larger than expected rise in

third-quarter profit, boosted by strong sales of copycat

medicines and its branded drugs to treat migraines and

Huntington's disease.

The world's largest generic drugmaker said on Wednesday it

earned 69 cents per diluted share excluding one-time items in

the July-September quarter, up from 60 cents per share a year

earlier. Revenue rose 13% to $4.33 billion.

Analysts had forecast earnings of 66 cents per share

ex-items for the Israel-based company on revenue of $4.12

billion, LSEG I/B/E/S data showed.